Cancer Cell Expression of Autotaxin Controls Bone Metastasis Formation in Mouse through Lysophosphatidic Acid-Dependent Activation of Osteoclasts
Open Access
- 17 March 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (3), e9741
- https://doi.org/10.1371/journal.pone.0009741
Abstract
Bone metastases are highly frequent complications of breast cancers. Current bone metastasis treatments using powerful anti-resorbtive agents are only palliative indicating that factors independent of bone resorption control bone metastasis progression. Autotaxin (ATX/NPP2) is a secreted protein with both oncogenic and pro-metastatic properties. Through its lysosphospholipase D (lysoPLD) activity, ATX controls the level of lysophosphatidic acid (LPA) in the blood. Platelet-derived LPA promotes the progression of osteolytic bone metastases of breast cancer cells. We asked whether ATX was involved in the bone metastasis process. We characterized the role of ATX in osteolytic bone metastasis formation by using genetically modified breast cancer cells exploited on different osteolytic bone metastasis mouse models. Intravenous injection of human breast cancer MDA-B02 cells with forced expression of ATX (MDA-B02/ATX) to inmmunodeficiency BALB/C nude mice enhanced osteolytic bone metastasis formation, as judged by increased bone loss, tumor burden, and a higher number of active osteoclasts at the metastatic site. Mouse breast cancer 4T1 cells induced the formation of osteolytic bone metastases after intracardiac injection in immunocompetent BALB/C mice. These cells expressed active ATX and silencing ATX expression inhibited the extent of osteolytic bone lesions and decreased the number of active osteoclasts at the bone metastatic site. In vitro, osteoclast differentiation was enhanced in presence of MDA-B02/ATX cell conditioned media or recombinant autotaxin that was blocked by the autotaxin inhibitor vpc8a202. In vitro, addition of LPA to active charcoal-treated serum restored the capacity of the serum to support RANK-L/MCSF-induced osteoclastogenesis. Expression of autotaxin by cancer cells controls osteolytic bone metastasis formation. This work demonstrates a new role for LPA as a factor that stimulates directly cancer growth and metastasis, and osteoclast differentiation. Therefore, targeting the autotaxin/LPA track emerges as a potential new therapeutic approach to improve the outcome of patients with bone metastases.Keywords
This publication has 52 references indexed in Scilit:
- Sharpening the edges of understanding the structure/function of the LPA1 receptor: Expression in cancer and mechanisms of regulationBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2008
- Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severityLife Sciences, 2007
- Reduced expression of autotaxin predicts survival in uveal melanomaBritish Journal of Ophthalmology, 2007
- Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cellsBreast Cancer Research and Treatment, 2006
- Lysophosphatidic acid induces chemotaxis in MC3T3-E1 osteoblastic cellsBone, 2006
- Lysophosphatidic acid cooperates with 1α,25(OH)2D3 in stimulating human MG63 osteoblast maturationProstaglandins & Other Lipid Mediators, 2006
- Autotaxin, a Secreted Lysophospholipase D, Is Essential for Blood Vessel Formation during DevelopmentMolecular and Cellular Biology, 2006
- The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastasesProceedings of the National Academy of Sciences of the United States of America, 2006
- Cloning, Chromosomal Localization, and Tissue Expression of Autotaxin from Human Teratocarcinoma CellsBiochemical and Biophysical Research Communications, 1996
- Identification of the molecular species of lysophosphatidic acid produced when platelets are stimulated by thrombinBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1989